Osteoporosis International

, Volume 27, Issue 2, pp 821–825 | Cite as

Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report

  • S. K. Ramchand
  • C. Y. Chiang
  • R. M. Zebaze
  • E. Seeman
Case Report

Abstract

We report that a postmenopausal woman with osteoporosis developed bilateral incomplete atypical femoral fractures (AFFs) after seven years of bisphosphonate therapy. Cessation of the bisphosphonate and treatment with teriparatide was associated with near complete radiological resolution of the AFFs. After 12 months without treatment, denosumab was commenced to prevent structural deterioration. Six months later she developed recurrent bilateral AFFs. This case highlights the management dilemma in patients with ongoing bone loss but prone to stress fractures associated with antiresorptive therapy. Stopping the antiresorptive is recommended but structural decay will recur predisposing to fragility fractures. If the antiresorptive is continued, bone material composition will be further compromised predisposing to atypical fractures. Teriparatide may assist healing of stress fractures and improvement in bone matrix composition. Later antiresosrptive therapy to preserve bone microstructure may compromise material composition.

Keywords

Atypical femoral fractures Denosumab Osteoporosis Teriparatide 

Notes

Compliance with ethical standards

Conflicts of interest

Roger M Zebaze and Ego Seeman are directors of StraxCorp and inventors of the algorithm for quantifying tissue mineralization density. No financial compensation was derived from this work. Sabashini K Ramchand and Cherie Y Chiang declare that they have no conflict of interest.

References

  1. 1.
    Zebaze R, Ghasem-Zadeh A, Mbala A, Seeman E (2013) A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone 54(1):8–20CrossRefPubMedGoogle Scholar
  2. 2.
    Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354(21):2250–2261CrossRefPubMedGoogle Scholar
  3. 3.
    Diab DL, Watts NB (2014) Denosumab in osteoporosis. Expert Opin Drug Saf 13(2):247–253CrossRefPubMedGoogle Scholar
  4. 4.
    Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55(2):495–500CrossRefPubMedGoogle Scholar
  5. 5.
    Karim L, Vashishth D (2012) Heterogeneous glycation of cancellous bone and its association with bone quality and fragility. PLoS One 7(4):e35047PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69(5):281–286CrossRefPubMedGoogle Scholar
  7. 7.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23CrossRefPubMedGoogle Scholar
  8. 8.
    Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52(1):360–365CrossRefPubMedGoogle Scholar
  9. 9.
    Murphy CM, Schindeler A, Cantrill LC, Mikulec K, Peacock L, Little DG (2014) PTH treatment increases bisphosphonate turnover in fracture repair in rats. J Bone Miner Res 30(6):1022–2029CrossRefGoogle Scholar
  10. 10.
    Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44(5):477–482CrossRefPubMedGoogle Scholar
  11. 11.
    Bardin MS, Iuliano-Burns S, Zajac J, Seeman E, Chiang C (2013) Patients with atypical femoral fractures have higher body mass index and femoral neck bone mineral density compared to patients with typical femoral fractures. Paper presented at: Endocrine Society of Australia - Annual Scientific Meeting; Sydney, Australia.Google Scholar
  12. 12.
    Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169–180CrossRefPubMedGoogle Scholar
  13. 13.
    Bala Y, Farlay D, Delmas PD, Meunier PJ, Boivin G (2010) Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewes. Bone 46(4):1204–1212CrossRefPubMedGoogle Scholar
  14. 14.
    Thompson RN, Armstrong CL, Heyburn G (2014) Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone 61:44–47CrossRefPubMedGoogle Scholar
  15. 15.
    Gallant MA, Brown DM, Hammond M, Wallace JM, Du J, Deymier-Black AC, Almer JD, Stock SR, Allen MR, Burr DB (2014) Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone 61:191–200PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2015

Authors and Affiliations

  • S. K. Ramchand
    • 1
  • C. Y. Chiang
    • 1
    • 2
  • R. M. Zebaze
    • 1
    • 2
  • E. Seeman
    • 1
    • 2
  1. 1.Department of EndocrinologyAustin HealthMelbourneAustralia
  2. 2.Department of Medicine, Austin HealthUniversity of MelbourneMelbourneAustralia

Personalised recommendations